Biotech Values

[Biowatch]

A difference of opinion makes a market. No hard feelings…

I’m personally disappointed in how lackluster or outright bad RVNC’s share price has performed AFTER they got FDA approval. It’s not what I expected.

They had a fair amount of time to manufacture their product. If they knew they would need to train people in how to administer it, I am surprised they didn’t address the issue sooner.

I was surprised at the length of time they anticipate to ramp up sales.

They had plenty of time to think about issues involving the product launch during the delay in the PDUFA date imposed by the Covid crisis, when the FDA was busy with more pressing concerns.